Evidence map›Paper›PMID 39899616›Full record

SynthesisPLoS neglected tropical diseases2025

Diagnostic, prognostic, and therapeutic potentials of gut microbiome profiling in human schistosomiasis: A comprehensive systematic review.

Martin Gael Oyono, Sebastien Kenmoe, Jean Thierry Ebogo Belobo, Leonel Javeres Mbah Ntepe, Mireille Kameni, Leonel Meyo Kamguia, Thabo Mpotje, Justin Komguep Nono

Abstract readSystematic Review
In one paragraph

Synthesis in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Martin Gael OyonoLaboratory of Microbiology, Infectious Diseases and Immunology, Institute of Medical Research and Medicinal Plant Studies (IMPM), Ministry of Scientific Research and Innovation, Yaoundé, Cameroon.
Sebastien KenmoeDepartment of Microbiology and Parasitology, University of Buea, Buea, Cameroon.
Jean Thierry Ebogo BeloboLaboratory of Microbiology, Infectious Diseases and Immunology, Institute of Medical Research and Medicinal Plant Studies (IMPM), Ministry of Scientific Research and Innovation, Yaoundé, Cameroon.
Leonel Javeres Mbah NtepeUnit of Immunobiology and helminth infections, Laboratory of Molecular Biology and Biotechnology, Institute of Medical Research and Medicinal plant Studies, Ministry of Scientific Research and Innovation, Yaoundé, Cameroon.
Mireille KameniUnit of Immunobiology and helminth infections, Laboratory of Molecular Biology and Biotechnology, Institute of Medical Research and Medicinal plant Studies, Ministry of Scientific Research and Innovation, Yaoundé, Cameroon.
Leonel Meyo KamguiaUnit of Immunobiology and helminth infections, Laboratory of Molecular Biology and Biotechnology, Institute of Medical Research and Medicinal plant Studies, Ministry of Scientific Research and Innovation, Yaoundé, Cameroon.
Thabo MpotjeAfrica Health Research Institute, Durban, Kwazulu-Natal, South Africa.
Justin Komguep NonoUnit of Immunobiology and helminth infections, Laboratory of Molecular Biology and Biotechnology, Institute of Medical Research and Medicinal plant Studies, Ministry of Scientific Research and Innovation, Yaoundé, Cameroon.ORCID https://orcid.org/0000-0001-6153-9729

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral studies have highlighted alteration in the gut microbiome associated with the onset and progression of diseases. Recognizing the potential of gut microbiota as biomarkers, this systematic review seeks to synthesize current data on the intricate relationship between the host gut microbiome profiles and their usefulness for the development of diagnostic, prognostic and therapeutic approaches to control human schistosomiasis.

methodsA systematic literature review was carried out by searching for relevant studies published until date, that is May 2024, using Medline, Embase, Global Health, Web of Science, and Global Index Medicus databases. The keywords used to select articles were "Gut microbiome", "Gut Microbiota", "Schistosomiasis", "Bilharziasis ", and "Human". Extracted data were analysed qualitatively from the selected articles.

resultsOf the 885 articles retrieved and screened, only 13 (1.47%) met the inclusion criteria and were included in this review. Of the included studies, 6 (46.2%) explored alterations of gut microbiome in schistosome-infected patients, 4 (30.7%) in patients with liver pathologies, and 3 (23.1%) in patients treated with praziquantel. Bacteria from the genera Bacteroides, Faecalibacterium, Blautia and Megasphaera were associated with S. japonicum and S. haematobium infection in school-aged children, whereas infection with S. mansoni rather associated with Klebsiella and Enterobacter. The gut microbiota signature in patient with schistosomiasis-induced liver pathology was reported only for S. japonicum, and the genus Prevotella appeared as a non-invasive biomarker of S. japonicum-associated liver fibrosis. For S. mansoni-infected school-aged children, it further appeared that the treatment outcome following praziquantel administration associated with the abundance in the gut microbiome of bacteria from the classes Fusobacteriales, Rickettsiales and Neisseriales.

conclusionThe host gut microbiome appears to be a valuable, non-invasive, but still poorly utilized, source of host biomarkers potentially informative for better diagnosing, prognosing and treating schistosomiasis. Further studies are therefore needed to comprehensively define such gut microbial biomarkers of human schistosomiasis and catalyse the informed development of gut microbiome-based tools of schistosomiasis control.

Indexed as

Gastrointestinal MicrobiomeSchistosomiasisAnimalsAnthelminticsBacteriaBiomarkersHumansPraziquantelPrognosisSchistosomaAnthelminticsBiomarkersPraziquantel

Identifiers

PMID39899616
PMCPMC11844881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.